uniQure

• uniQure, a commercial-stage biotechnology company focused on developing gene therapies for severe diseases, successfully raised USD 300 million in equity financing, which was increased to USD 345 million following the exercise in full of the underwriters’ 15% overallotment option
• The transaction was priced at USD 47.50 per share, representing no discount vis-à-vis the pre-launch closing price on Wednesday 24 September 
• The transaction was launched on the back of topline three-year Phase I/II data for its lead asset, AMT-130—an AAV gene therapy for Huntington’s disease and the first potential disease-modifying treatment for this condition. A Biologics License Application (BLA) submission is anticipated in the first quarter of 2026, with a potential commercial launch later that year
• Van Lanschot Kempen played an instrumental role in securing orders from new tier-1 long-only and international life science investors 
• uniQure intends to use the net proceeds from this offering to fund its AMT-130 program through BLA submission and potential launch, advance other pipeline assets, pursue business development initiatives and research projects, and support general corporate purposes
• Van Lanschot Kempen acted as Joint Bookrunner and was the only European bank in a US-dominated banking syndicate, and is proud to support uniQure for the first time in a successful equity raise

• uniQure is dedicated to transforming the lives of patients with severe genetic diseases through innovative gene therapies
• Their leadership in the field of genomic medicine is demonstrated by the regulatory approval of Hemgenix®, the first gene therapy for haemophilia B, which has been outlicensed to CSL
• The company has developed a broad pipeline of gene therapies, with programs at multiple stages of development, focusing on Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases
• uniQure is headquartered in Amsterdam, the Netherlands, with a US office in Lexington, Massachusetts, and is listed on the Nasdaq in the US (QURE)

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Bookrunner in the secondary sell-down of existing BioArctic shares for SEK 720 million
• Financial Adviser to Galapagos in the sale of a portfolio of oncology and immunology programs to Onco3R
• Co-Manager in the USD 748 million Capital Increase by Abivax
• Financial Adviser in MaaT Pharma’s €38 million venture debt facility from the European Investment Bank
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris
• Lead Manager in the USD 345 million Capital Increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank